Syndax Pharmaceuticals, Inc. (SNDX)
收市後：
| 前收市價 | 20.57 |
| 開市 | 20.59 |
| 買盤 | 21.00 x 100 |
| 賣出價 | 21.08 x 200 |
| 今日波幅 | 20.48 - 21.24 |
| 52 週波幅 | 11.22 - 25.34 |
| 成交量 | |
| 平均成交量 | 1,093,519 |
| 市值 | 1.79B |
| Beta 值 (5 年，每月) | 0.98 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.98 |
| 業績公佈日 | 2024年5月06日 - 2024年5月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 35.27 |
ZacksSyndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
Insider MonkeySyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript February 27, 2024 Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.99. Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone. […]
ZacksSyndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
